Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-17
2009-12-01
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S350000, C544S359000, C546S152000, C546S192000, C546S268100, C548S579000, C549S059000, C549S505000
Reexamination Certificate
active
07625900
ABSTRACT:
Substituted tetrahydropyrrolopyrazine compounds corresponding to the formula I:processes for their preparation, pharmaceutical compositions comprising these compounds and the use of these compounds for the treatment and/or inhibition of pain and other disorders or disease states at least partly mediated by KCNQ2/3 K+channels.
REFERENCES:
patent: 4188389 (1980-02-01), Jirkovsky
patent: 2002/0128277 (2002-09-01), Dworetzky et al.
patent: 2097465 (1993-12-01), None
patent: 0 572 863 (1993-12-01), None
patent: WO 94/29315 (1994-12-01), None
patent: WO 03/024967 (2003-03-01), None
patent: WO 03/084955 (2003-10-01), None
patent: WO 2004/029040 (2004-04-01), None
patent: WO 2004/052864 (2004-06-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Patani, et al. Chem. Rev., 96, 1996, pp. 3147-3176.
German Search Report dated Oct. 28, 2006 with English translation of relevant portions (nine (9) pages).
Bennett, Gary J., et al., “A Peripheral Mononeuropathy in Rat That Produces Disorders of Pain Sensation Like Those Seen in Man,” Pain, 1988, pp. 87-107, vol. 33, 1988 Elsevier Science Publishers B.V.
Blackburn-Munro, Gordon, et al., “The Anticonvulsant Retigabine Attenuates Nociceptive Behaviors in Rat Models of Persistent and Neuropathic Pain,” European Journal of Pharmacology, 2003, pp. 109-116, vol. 460, 2003 Elsevier Science Publishers B.V.
De Sarro, Giovambattista, et al., “Influence of Retigabine on the Anticonvulsant Activity of Some Antiepileptic Drugs Against Audiogenic Seizures in DBA/2 Mice,” Naunyn-Schmiedeberg's Arch Pharmacology, 2001, pp. 330-336, vol. 363.
Dost, R., et al., “The Anti-Hyperalgesic Activity of Retigabine is Mediated by KCNQ Potassium Channel Activation,” Naunyn-Schmiedeberg's Arch Pharmacology, 2004, pp. 382-390, vol. 369, Springer-Verlag 2004.
Gribkoff, Valentin K., “The Therapeutic Potential of Neuronal KCNQ Channel Modulators,” Expert Opinion Ther. Targets, 2003, pp. 737-748, vol. 7, No. 6, Ashley Publications Ltd. 2003.
Hamill, O.P., et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,” Pfluegers Archiv European Journal of Physiology, 1981, pp. 85-100, vol. 391, Springer-Verlag 1981.
Kim, Sun Ho, et al., “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,” Pain, 1992, pp. 355-363, vol. 50, 1992 Elsevier Science Publishers B.V.
Korsgaard, M.P.G., et al., “Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine Via Activation of Neuronal Kv7 Channels,” The Journal of Pharmacology and Experimental Therapeutics, 2005, pp. 282-292, vol. 314, No. 1, 2005 The American Society for Pharmacology and Experimental Therapeutics.
Nielsen, Alexander Norup, et al., “Pharmacological Characterisation of Acid-Induced Muscle Allodynia in Rats,” European Journal of Pharmacology, 2004, pp. 93-103, vol. 487, 2004 Elsevier B.V.
Passmore, Gayle M., et al., “KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy,” The Journal of Neuroscience, Aug. 6, 2003, pp. 7227-7236, vol. 23, No. 18, 2003 Society for Neuroscience.
Streng, Tomi, et al., “Urodynamic Effects of the K+ Channel (KCNQ) Opener Retigabine in Freely Moving, Conscious Rats,” The Journal of Urology, Nov. 2004, pp. 2054-2058, vol. 172, 2004 American Urological Association.
Wickenden, Alan D., et al., “KCNQ Potassium Channels: Drug Targets for the Treatment of Epilepsy and Pain,” Expert Opinion Ther. Patents, 2004, vol. 14, No. 4, 2004 Ashley Publications Ltd.
Shirude, P.S., Kumar, V.A., Ganesh, K.N., (2S,5R/2R,5S)-Aminoethylpipecolylaepip-aegPNA chimera: synthesis and duplex/triplex stability, Tetrahedron 60: 9485-9492 (2004).
Nakao, K. et al., Quantitative Structure-Activity Analyses of Novel Hydroxyphenylurea Derivatives as Antioxidants,Bioorg. Med. Chem., 6:849-868 (1998).
B. L. Bray et al., N-(Triisopropylsilyl)pyrrole, A progenitor “par excellence” of 3-substituted pyrroles,J. Org. Chem., 55(26):6317-6328 (1990).
M. A. Marques et al, Toward an Understanding of the Chemical Etiology for DNA Minor-Broove Recognition by Polyamides,Helvetica Chimica Acta85(12):4485-4517 (2002).
I. Jirkovski und R. Baudy, A Facile, Large-Scale Preparation of 1H-Pyrrole-1-ethanamine and Syntheses of Substituted Pyrrolo[1,2-a]pyrazines and Hydro Derivatives Thereof,Synthesis, pp. 481-483, Georg Thieme Verlag, Stuttgart—New York (1981).
English translation of the International Preliminary Report on Patentability dated May 15, 2009 (Ten (10) pages).
Bahrenberg Gregor
Christoph Thomas
Frank Robert
Kuehnert Sven
Merla Beatrix
Crowell & Moring LLP
Gruenenthal GmbH
Willis Douglas M
Wilson James O
LandOfFree
Sutstituted tetrahydropyrrolopyrazine compounds and the use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sutstituted tetrahydropyrrolopyrazine compounds and the use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sutstituted tetrahydropyrrolopyrazine compounds and the use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131326